Sections
Title | Starting Page | Number of Pages |
---|
1 Table of Contents | 5 | 5 |
1.1 List of Tables | 8 | 1 |
1.2 List of Figures | 8 | 2 |
2 Introduction | 10 | 20 |
2.1 Disease Introduction | 10 | 1 |
2.2 Epidemiology | 11 | 1 |
2.3 Symptoms | 12 | 1 |
2.4 Etiology and Pathophysiology | 13 | 1 |
2.4.1 Adenocarcinoma | 14 | 1 |
2.4.1.1 Histology | 14 | 1 |
2.4.1.2 Molecular Characterization and Biomarkers | 14 | 2 |
2.4.2 Squamous-Cell Carcinoma | 16 | 1 |
2.4.2.1 Histology | 17 | 1 |
2.4.2.2 Molecular Characterization and Biomarkers | 17 | 2 |
2.4.3 Large-Cell Carcinoma | 19 | 1 |
2.4.3.1 Histology | 19 | 1 |
2.4.3.2 Molecular Characterization and Biomarkers | 19 | 1 |
2.4.4 Immunotherapy | 20 | 1 |
2.5 Diagnosis | 20 | 3 |
2.6 Prognosis | 23 | 1 |
2.7 Treatment Guidelines and Options | 23 | 1 |
2.7.1 Treatment Algorithm | 24 | 1 |
2.7.2 First-Line Treatment | 25 | 1 |
2.7.3 Maintenance Therapy | 26 | 1 |
2.7.4 Second-Line Treatment | 27 | 1 |
2.7.5 Third-Line Therapy | 28 | 1 |
2.7.6 Adjuvant Therapy | 29 | 1 |
3 Marketed Products | 30 | 14 |
3.1 Overview | 30 | 1 |
3.2 Chemotherapies | 30 | 1 |
3.2.1 Alimta (pemetrexed) Eli Lilly | 30 | 1 |
3.2.2 Abraxane (paclitaxel) Celgene | 31 | 1 |
3.3 Tarceva (erlotinib) Roche | 32 | 1 |
3.4 Iressa (gefitinib) AstraZeneca | 33 | 1 |
3.5 Gilotrif (afatinib) Boehringer Ingelheim | 34 | 1 |
3.6 Xalkori (crizotinib) Pfizer | 35 | 1 |
3.7 Avastin (bevacizumab) Roche | 36 | 1 |
3.8 Opdivo (nivolumab) Bristol-Myers Squibb | 37 | 1 |
3.9 Alecensa (alectinib) Roche | 38 | 1 |
3.10 Conclusion | 39 | 1 |
3.11 Comparative Efficacy and Safety of Marketed Products | 40 | 4 |
4 Pipeline Analysis | 44 | 31 |
4.1 Overview | 44 | 1 |
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type | 45 | 1 |
4.3 Pipeline by Molecular Target | 46 | 3 |
4.4 Promising Pipeline Candidates | 49 | 1 |
4.4.1 Ipilimumab Bristol-Myers Squibb | 49 | 1 |
4.4.1.1 Forecast | 50 | 1 |
4.4.2 Custirsen OncoGenex | 51 | 1 |
4.4.2.1 Forecast | 52 | 1 |
4.4.3 Atezolizumab Roche | 52 | 1 |
4.4.3.1 Forecast | 53 | 1 |
4.4.4 Necitumumab Eli Lilly | 54 | 1 |
4.4.4.1 Forecast | 55 | 1 |
4.4.5 Rociletinib Clovis | 55 | 1 |
4.4.5.1 Forecast | 56 | 1 |
4.4.6 Vaxira Recombio | 57 | 1 |
4.4.6.1 Forecast | 58 | 1 |
4.4.7 Keytruda Merck | 58 | 1 |
4.4.7.1 Forecast | 59 | 1 |
4.4.8 TG4010 Transgene | 60 | 1 |
4.4.8.1 Forecast | 61 | 1 |
4.4.9 Veliparib AbbVie | 61 | 1 |
4.4.9.1 Forecast | 62 | 1 |
4.4.10 Abemaciclib Eli Lilly | 63 | 1 |
4.4.10.1 Forecast | 63 | 1 |
4.4.11 Bavituximab Peregrine Pharmaceuticals | 64 | 1 |
4.4.11.1 Forecast | 65 | 1 |
4.4.12 Cyramza (Ramucirumab) Eli Lilly | 65 | 1 |
4.4.12.1 Forecast | 66 | 1 |
4.4.13 Zykadia (ceritinib/LDK378) Novartis | 67 | 1 |
4.4.13.1 Forecast | 68 | 1 |
4.4.14 Tagrisso (osimertinib/AZD-9291) AstraZeneca | 68 | 1 |
4.4.14.1 Forecast | 69 | 1 |
4.4.15 Dacomitinib Pfizer | 70 | 1 |
4.4.16 Selumetinib AstraZeneca | 71 | 1 |
4.5 Comparative Efficacy and Safety of Pipeline Products | 72 | 1 |
4.6 Product Competitiveness Framework | 73 | 2 |
5 Clinical Trial Analysis | 75 | 10 |
5.1 Failure Rate | 75 | 1 |
5.1.1 Overall Failure Rate | 75 | 1 |
5.1.2 Failure Rate by Phase and Molecule Type | 75 | 1 |
5.1.3 Failure Rate by Phase and Molecular Target | 76 | 1 |
5.2 Clinical Trial Size | 77 | 1 |
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development | 78 | 1 |
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development | 78 | 1 |
5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development | 79 | 1 |
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development | 80 | 1 |
5.3 Clinical Trial Duration | 81 | 1 |
5.3.1 Trial Duration by Molecule Type and Stage of Development | 82 | 1 |
5.3.2 Trial Duration by Molecular Target and Stage of Development | 82 | 1 |
5.4 Summary of Clinical Trial Metrics | 83 | 2 |
6 Multi-scenario Forecast | 85 | 16 |
6.1 Overview | 85 | 1 |
6.2 Asia-Pacific Market | 85 | 2 |
6.3 India | 87 | 1 |
6.3.1 Treatment Usage Patterns | 87 | 1 |
6.3.2 Annual Cost of Therapy | 88 | 1 |
6.3.3 Market Size | 89 | 1 |
6.4 China | 90 | 1 |
6.4.1 Treatment Usage Patterns | 90 | 1 |
6.4.2 Annual Cost of Therapy | 91 | 1 |
6.4.3 Market Size | 92 | 1 |
6.5 Australia | 93 | 1 |
6.5.1 Treatment Usage Patterns | 93 | 1 |
6.5.2 Annual Cost of Therapy | 93 | 1 |
6.5.3 Market Size | 94 | 1 |
6.6 South Korea | 95 | 1 |
6.6.1 Treatment Usage Patterns | 95 | 1 |
6.6.2 Annual Cost of Therapy | 96 | 1 |
6.6.3 Market Size | 97 | 1 |
6.7 Japan | 98 | 1 |
6.7.1 Treatment Usage Patterns | 98 | 1 |
6.7.2 Annual Cost of Therapy | 99 | 1 |
6.7.3 Market Size | 99 | 2 |
7 Market Dynamics (Drivers and Barriers) | 101 | 3 |
7.1 Drivers | 101 | 1 |
7.1.1 Increasing pollution and passive smoking to drive the incidence | 101 | 1 |
7.1.2 Increasing Elderly Population and Incidence of NSCLC | 101 | 1 |
7.1.3 The Availability of Novel First- and Second-Line Therapy Options in Pipeline | 101 | 1 |
7.1.4 Increase in Mutation Testing to Drive Market Growth | 101 | 1 |
7.1.5 Diversified Healthcare Reform to Boost Market Growth | 102 | 1 |
7.1.6 Diversified Health Insurance System to Help Nurture Growth | 102 | 1 |
7.2 Barriers | 102 | 1 |
7.2.1 Patent Expiration of Branded Therapies to Affect NSCLC Market Growth | 102 | 1 |
7.2.2 High Prices of Therapeutics to Slow Down Market Growth | 102 | 1 |
7.2.3 Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India | 103 | 1 |
8 Deals and Strategic Consolidations | 104 | 9 |
8.1 Co-development Deals | 104 | 2 |
8.1.1 Key Co-development Deals | 106 | 1 |
8.1.1.1 Pfizer Enters Co-development Agreement with Merck | 106 | 1 |
8.1.1.2 Merck Enters Co-development Agreement with Endocyte | 106 | 1 |
8.1.1.3 GlobeImmune Enters Agreement with Celgene | 107 | 1 |
8.1.1.4 Amgen Enters Co-development Agreement with Takeda Pharmaceutical | 107 | 1 |
8.1.1.5 Roche Enters Co-development Agreement with Immatics | 107 | 1 |
8.2 Licensing Deals | 107 | 4 |
8.2.1 Key Licensing Deals | 111 | 1 |
8.2.1.1 Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 | 111 | 1 |
8.2.1.2 Novartis Enters Licensing Agreement with Antisoma | 111 | 1 |
8.2.1.3 Ariad Enters Collaboration Agreement with Merck | 111 | 1 |
8.2.1.4 Astellas Enters Licensing Agreement with AVEO for Tivozanib | 111 | 1 |
8.2.1.5 Geron Enters Licensing Agreement with Janssen | 112 | 1 |
9 Appendix | 113 | 32 |
9.1 All Pipeline Drugs by Stage of Development | 113 | 18 |
9.1.1 Discovery | 113 | 1 |
9.1.2 Preclinical | 114 | 4 |
9.1.3 Investigational New Drug/ Clinical Trial Authorization-filed | 118 | 1 |
9.1.4 Phase I | 119 | 4 |
9.1.5 Phase II | 123 | 5 |
9.1.6 Phase III | 128 | 2 |
9.1.7 Pre-registration | 130 | 1 |
9.2 Summary of Multi-scenario Market Forecasts to 2022 | 130 | 3 |
9.2.1 Asia-Pacific | 130 | 1 |
9.2.2 India | 131 | 1 |
9.2.3 China | 131 | 1 |
9.2.4 Australia | 131 | 1 |
9.2.5 South Korea | 132 | 1 |
9.2.6 Japan | 132 | 1 |
9.3 References | 132 | 6 |
9.4 Abbreviations | 138 | 2 |
9.5 Research Methodology | 140 | 5 |
9.5.1 Secondary Research | 140 | 1 |
9.5.2 Marketed Product Profiles | 141 | 1 |
9.5.3 Late-Stage Pipeline Candidates | 141 | 1 |
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products | 141 | 1 |
9.5.5 Product Competitiveness Framework | 141 | 1 |
9.5.6 Pipeline Analysis | 142 | 1 |
9.5.6.1 Overall Pipeline | 142 | 1 |
9.5.6.2 Clinical Trials | 142 | 1 |
9.5.6.2.1 Failure Rate | 142 | 1 |
9.5.6.2.2 Clinical Trial Size | 142 | 1 |
9.5.6.2.3 Clinical Trial Duration | 143 | 1 |
9.5.6.2.4 Clinical trial Endpoint Analysis | 143 | 1 |
9.5.7 Forecasting Model | 143 | 1 |
9.5.8 Deals Data Analysis | 144 | 1 |
9.6 Contact Us | 144 | 1 |
9.7 Disclaimer | 144 | 1 |